Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial

Authors:

Abstract
No abstract available
Funding Information
  • National Center for Advancing Translational Sciences (1UL1TR002541-01)
  • Harvard Catalyst (1K23AI185318\u201301A1)
  • Harvard Catalyst (R01AI179917)
  • Harvard Catalyst (1UL1TR002541-01)
  • Harvard Catalyst (AI007061)
  • National Institute of Allergy and Infectious Diseases (AI007061)
  • National Institute of Allergy and Infectious Diseases (R01AI179917)
  • National Institute of Allergy and Infectious Diseases (RO1AI042347-29)
  • National Institute of Allergy and Infectious Diseases (5-UM1-AI-069412-19)
  • National Institutes of Health
  • Howard Hughes Medical Institute
  • Wellcome Trust (218443/Z/19/Z)

This publication has 29 references indexed in Scilit: